You are here

Durvalumab Shows Promise in Lung and Head-and-Neck Cancers

Monoclonal antibody maximizes T-cell activation

Positive efficacy and safety data have been reported for durvalumab (AstraZeneca/MedImmune) in two cohorts of patients with either advanced non–small-cell lung cancer (NSCLC) or advanced head-and-neck squamous cell carcinoma (HNSCC).

Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1) and is designed to help activate the immune system against tumors. Durvalumab blocks PD-L1 interaction with programmed death-1 (PD-1) and the costimulatory ligand CD80 on T cells, which maximizes T-cell activation. By inhibiting PD-L1, durvalumab helps increase T-cell activity against tumors to counter their efforts to evade the immune system.

Follow-up results from a phase 1/2 study of durvalumab as monotherapy in patients with advanced NSCLC showed that those with high programmed death ligand-1 (PD-L1)-expressing tumors had a higher objective response rate (ORR) and overall survival (OS) compared with patients with low or no PD-L1 expression. The ORR was 25% in patients with high PD-L1 tumors (n = 154) compared with 6% in patients with low PD-L1 tumors (n = 116). In those with high-PD-L1 expression, OS was 80%, 69%, and 66% in those receiving one line of therapy (n = 58), two lines of therapy (n = 179), or three or more lines of therapy (n = 250), respectively. OS in the group with low PD-L1 expression was 56%, 66%, and 53%, respectively.

In the cohort with metastatic/recurrent HNSCC (n = 62), all of the evaluable patients showed an ORR of 11%; this increased to 18% in patients with high PD-L1 tumors (n = 22). OS was 62% and 42% in all evaluable patients at six and 12 months, respectively. 

AstraZeneca is developing durvalumab as the primary molecule in a combination-focused approach to strengthening the immune system against cancer. In 2015, durvalumab received a fast-track designation from the FDA for the treatment of patients with PD-L1–positive metastatic HNSCC, and in 2016, it was granted breakthrough therapy status for the treatment of patients with PD-L1–positive inoperable or metastatic urothelial bladder cancer whose tumors has progressed during or after one standard platinum-based regimen.

Source: PipelineReview; October 11, 2016.

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial